Catalyst expands Board to 7 with appointment of Dr. Daniel Curran

CATALYST PHARMACEUTICALS, INC.

Board increased from 6 to 7 members; Dr. Curran appointed effective immediately.
Curran brings 25+ years pharma experience; served as SVP at Takeda Rare Genetics (2019-2023).
Currently CEO of Timberlyne Therapeutics and Managing Partner at Mountainfield Venture Partners.

item 5.02 item 9.01

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-172653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.